# US 2026/0295036 A1 · Vaccine for treating allergies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0295036 A1
- Document ID: US20260295036A1
- Status: Published application
- Kind: A1
- Application number: 19/127,971
- Filed: 2022-11-07
- Published: 2026-10-01
- Earliest claimed: 2022-11-07
- Assignees: Worg Pharmaceuticals (Zhejiang) Co., Ltd.
- Applicants: Worg Pharmaceuticals (Zhejiang) Co., Ltd
- Inventors: Alexander KARAULOV; Rudolf VALENTA; Petr V. GLYBOCHKO; Antonina KARSONOVA; Ksenja RIABOVA; Daria TRIFONOVA; Mirela CURIN; Marianne Van HAGE
- Web page: https://patentgrep.com/patent/US20260295036A1

## CPC

- A61K 39/35: Allergens
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/47: from mammals
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A peptide consisting of 20 to 30 amino acid residues derived from amino acid position 120 to 171 of mature allergen Fel d 4 is provided as well as fusion proteins comprising said peptide. A vector includes a nucleic acid molecule encoding the peptide. A vaccine formulation includes the peptide is effective in prevention or treatment of a furry animal allergy.

## Claims

### Claim 1

A peptide consisting of 20 to 30 amino acid residues derived from amino acid position 120 to 171 of mature allergen Fel d 4.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide is derived from amino acid position 130 to 171, preferably from amino acid position 140 to 171, more preferably from amino acid position 145 to 171, more preferably from amino acid position 146 to 171, of mature Fel d 4.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein Fel d 4 comprises or consists of SEQ ID No: 1.

### Claim 4 (depends on 1)

The peptide of claim 1, wherein the peptide comprises or consists of amino acid sequence SEQ ID No: 3.

### Claim 5 (depends on 1)

A fusion protein or a conjugate comprising at least one peptide according to claim 1.

### Claim 6 (depends on 5)

The fusion protein or conjugate of claim 5, wherein the at least one peptide is conjugated or fused to at least one allergen fragment and/or at least one carrier protein.

### Claim 7 (depends on 6)

The fusion protein or conjugate of claim 6, wherein the at least one allergen fragment is derived from at least one furry animal allergen, preferably from at least one cat allergen.

### Claim 8 (depends on 7)

The fusion protein or conjugate of claim 7, wherein the at least one cat allergen is selected from the group consisting of Fel d 1 chain 1, Fel d 1 chain 2, Fel d 2, Fel d 3, Fel d 5, Fel d 6, Fel d 7 and Fel d 8, preferably from the group consisting of Fel d 1 chain 1, Fel d 1 chain 2, and Fel d 7, more preferably from the group consisting of Fel d 1 chain 1, Fel d 1 chain 2, and Fel d 7.

### Claim 9 (depends on 6)

The fusion protein or conjugate of claim 6, wherein the at least one allergen fragment comprises or consists of 20 to 40 amino acid residues.

### Claim 10 (depends on 8)

The fusion protein or conjugate of claim 8, wherein the at least one allergen fragment of the at least one cat allergen is derived from and comprises the N-terminal end or the C-terminal end of said at least one cat allergen.

### Claim 11 (depends on 8)

The fusion protein or conjugate of claim 8, wherein the at least one allergen fragment derived from Fel d 1 chain 1 comprises or consists of amino acid residues 1 to 34 of mature Fel d 1 chain 1.

### Claim 12 (depends on 8)

The fusion protein or conjugate of claim 8, wherein the at least one allergen fragment derived from Fel d 1 chain 2 comprises or consists of amino acid residues 81 to 109 of mature Fel d 1 chain 2.

### Claim 13 (depends on 8)

The fusion protein or conjugate of claim 8, wherein the at least one allergen fragment derived from Fel d 7 comprises or consists of amino acid residues 61 to 97 and/or amino acid residues 124 to 162 of mature Fel d 7.

### Claim 14 (depends on 6)

The fusion protein or conjugate of claim 6, wherein the carrier protein is a viral protein or a fragment thereof consisting of 50 to 300, preferably 60 to 250, more preferably 80 to 200, more preferably 100 to 200, amino acid residues.

### Claim 15 (depends on 14)

The fusion protein or conjugate of claim 14, wherein the viral protein is a capsid protein.

### Claim 16 (depends on 14)

The fusion protein or conjugate of claim 14, wherein the viral protein is derived from a virus of the hepadnaviridae family.

### Claim 17 (depends on 16)

The fusion protein or conjugate of claim 16, wherein the virus of the hepadnaviridae family is a Hepatitis B virus.

### Claim 18 (depends on 17)

The fusion protein or conjugate of claim 17, wherein the viral protein of the Hepatitis B virus is PreS, PreS1 or PreS2.

### Claim 19 (depends on 6)

The fusion protein or conjugate of claim 6, wherein the carrier protein comprises or consists of amino acid sequence SEQ ID No: 4.

### Claim 20 (depends on 1)

The fusion protein or conjugate of, wherein the fusion protein comprises at least two peptides according to claim 1.

### Claim 21 (depends on 6)

The fusion protein or conjugate of claim 6, wherein two to eight, preferably two to six, of the at least one peptide and two to eight, preferably two to six, of at least one allergen fragment are fused to the N-terminal end and the C-terminal end of the at least one carrier protein.

### Claim 22 (depends on 20)

The fusion protein or conjugate of claim 20, wherein two peptides of the at least one peptide are located adjacent to each other within the fusion protein.

### Claim 23 (depends on 6)

The fusion protein or conjugate of claim 6, wherein the fusion protein comprises two peptides comprising or consisting of amino acid residues 146 to 171 of mature Fel d 4, two allergen fragments comprising or consisting of amino acid residues 1 to 34 of mature Fel d 1 chain 1, two allergen fragments comprising or consisting of amino acid residues 81 to 109 of mature Fel d 1 chain 2, two allergen fragments comprising or consisting of amino acid residues 81 to 109 of mature Fel d 1 chain 2, two allergen fragments comprising or consisting of amino acid residues 61 to 97 of mature Fel d 7 and two allergen fragments comprising or consisting of amino acid residues 124 to 162 of mature Fel d 7.

### Claim 24 (depends on 6)

The fusion protein or conjugate of claim 6, wherein said fusion protein comprises or consists of amino acid sequence SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, SEQ ID No: 12, SEQ ID No: 13 or SEQ ID No: 14, preferably SEQ ID No: 5, SEQ ID No: 7, SEQ ID No: 9, SEQ ID No: 11 or SEQ ID No: 13.

### Claim at position 25

25-26. (canceled)

### Claim 27 (depends on 1)

Nucleic acid molecule encoding a peptide according to claim 1.

### Claim 28 (depends on 27)

Vector comprising a nucleic acid molecule according to claim 27.

### Claim 29 (depends on 27)

Host cell comprising a nucleic acid molecule according to claim 27.

### Claim 30 (depends on 1)

Vaccine formulation comprising a peptide according to claim 1.

### Claim 31 (depends on 30)

Vaccine formulation according to claim 30 for the use in the prevention or treatment of a furry animal allergy, preferably a cat, dog and/or horse allergy.

### Claim 32 (depends on 30)

Vaccine formulation according to claim 30, wherein said formulation comprises 10 ng to 1 g, preferably 100 ng to 10 mg, especially 0.5 μg to 200 μg of said fusion protein, nucleic acid molecule or vector.

### Claim 33 (depends on 30)

Vaccine formulation according to claim 30, wherein said formulation further comprises at least one adjuvant, pharmaceutical acceptable excipient and/or preservative.
